Combined modality therapy for unresectable stage III non-small cell lung cancer: New chemotherapy combinations

Chest

Volumn 117, Issue 4 SUPPL. 1, 2000, Pages 127S-132S

  Belani, Chandra P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Combined modality; Esophagitis; Non small cell lung cancer; Radiosensitization; Survival; Therapy; Thoracic radiation

Indexed keywords

CARBOPLATIN; CISPLATIN DERIVATIVE; PACLITAXEL;

CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FATIGUE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 0034004673     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12:539-547
2. Perez CA, Stanley K, Grundy G, et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the Radiation Therapy Oncology Group. Cancer 1982; 50:1091-1099
3. Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990; 113:33-38
4. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with radiation therapy oncology group stage III non-small cell lung carcinoma; report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990; 8:1543-1555
5. Saunders MI, Dische S, Grosch EJ, et al. Experience with CHART. Int J Radiat Oncol Biol Phys 1991; 21:871-878
6. Saunders MI, Dische S, Barrett A, et al. Randomized multicenter trials of CHART vs conventional radiotherapy in head and neck and non-small cell lung cancer: an interim report. CHART Steering Committee. Br J Cancer 1996; 73:1455-1462
7. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma [letter]. J Natl Cancer Inst 1992; 84:58
8. Dillman RO, Seagren SL, Herndon J, et al. Randomized trial of induction chemotherapy plus radiation therapy vs RT alone in stage III non-small cell lung cancer (NSCLC): five-year follow-up of CALGB 84-33 [abstract 1092]. Proc Am Soc Clin Oncol 1993; 12:317
9. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323:940-945
10. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87:198-205
11. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-530
12. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996; 14:1065-1070
13. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995; 13:452-458
14. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced unresectable, non-small cell lung cancer: a metaanalysis. Ann Intern Med 1996; 125:723-728
15. Belani CP, Ramanathan RK. Combined modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents. Chest 1997; 113(suppl): 53S-61S
16. Choy H, Browne MJ. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol 1995; 22:70-74
17. Tishler RB, Geard CR, Hall EJ, et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992; 52:3495-3497
18. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332:1004-1014
19. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85:384-388
20. Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993; 85:388-394
21. Muggia FM, Vafai D, Natale R, et al. Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials. Semin Oncol 1995; 22:63-66
22. Belani CP, Aisner J, Hiponia D, et al. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin Oncol 1995; 22:7-12
23. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 16:1860-1870
24. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin for advanced lung cancer: preliminary results of a Vanderbilt University phase II trial-LUN-46. Semin Oncol 1995; 22:30-33
25. Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 1994; 12: 2682-2686
26. Kawasaki M, Nakanisi Y, Kuwano K, et al. The utility of p53 immunostaining for the transbronchial biopsy specimens of lung cancer: p53 overexpression may predict poor prognosis and chemoresistance in advanced non-small cell lung cancer [abstract 40]. Proc Am Soc Clin Oncol 1996; 15:94
27. Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma. Cancer 1996; 78:1203-1210
28. Belani CP, Aisner J, Hiponia D, et al. Paclitaxel and carboplatin with concurrent thoracic radiotherapy for regionally advanced non-small cell lung cancer (NSCLC) [abstract 1201]. Proc Am Soc Clin Oncol 1996; 15:396
29. Choy H. Concurrent paclitaxel, carboplatin and radiation therapy for non-small cell lung cancer [abstract 269]. Lung Cancer 1997; 18(suppl 1):70
30. Choy H, Akerley W, Safran H, et al. Phase II trial of weekly paclitaxel, carboplatin and concurrent radiation therapy for locally advanced non-small cell lung cancer (NSCLC) [abstract 1637]. Proc Am Soc Clin Oncol 1997; 16:456A
31. Choy H, DeVore RD, Hande KR, et al. Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial [abstract 1794]. Proc Am Soc Clin Oncol 1998; 17:467A
32. Langer CJ, Movsas B, Hudes R, et al. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center Study 94-001. Semin Oncol 1997; 24(suppl 12):S89-S95
33. Hudes R, Langer C, Movsas B, et al. Induction paclitaxel (Taxol) and carboplatin (CBDCA) followed by concurrent chemoradiotherapy (TRT-CT) in unresectable, locally advanced non-small cell lung carcinoma (NSCLC): report of FCCC 94-001 [abstract 1609]. Proc Am Soc Clin Oncol 1997; 16:448A
34. Rathmann J, Rigas JR, Leopold KA, et al. Daily paclitaxel and thoracic radiation therapy for the treatment of stage II and III non-small cell lung cancer (NSCLC) [abstract 1722]. Proc Am Soc Clin Oncol 1997; 16:478A
35. Wagner H, Antonia SJ, Williams CC, et al. Concurrent paclitaxel/cisplatin (PC) with thoracic radiation (TR) in patients with stage IIIA/B non-small cell lung cancer (NSCLC) [abstract 1610]. Proc Am Soc Clin Oncol 1997; 16:448A